Strategies to Prevent Brain Metastasis in High-Risk Non–Small-Cell Lung Cancer: Lessons Learned From a Randomized Study of Maintenance Temozolomide Versus Observation

D. Hunter Boggs; H. Ian Robins; Corey J. Langer; Anne M. Traynor; Maurice J. Berkowitz; Minesh P. Mehta

doi:10.1016/j.cllc.2014.06.008

Strategies to Prevent Brain Metastasis in High-Risk Non–Small-Cell Lung Cancer: Lessons Learned From a Randomized Study of Maintenance Temozolomide Versus Observation

D. Hunter Boggs, H. Ian Robins, Corey J. Langer, Anne M. Traynor, Maurice J. Berkowitz, Minesh P. Mehta

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Clinical Lung Cancer
Volume	15
DOIs	https://doi.org/10.1016/j.cllc.2014.06.008
State	Published - Jan 11 2014

Disciplines

Medicine and Health Sciences
Pathology

Access to Document

10.1016/j.cllc.2014.06.008License: Unspecified

Cite this

@article{3249272f42ad4c51aff6ba22a074a44e,

title = "Strategies to Prevent Brain Metastasis in High-Risk Non–Small-Cell Lung Cancer: Lessons Learned From a Randomized Study of Maintenance Temozolomide Versus Observation",

author = "Boggs, \{D. Hunter\} and Robins, \{H. Ian\} and Langer, \{Corey J.\} and Traynor, \{Anne M.\} and Berkowitz, \{Maurice J.\} and Mehta, \{Minesh P.\}",

note = "The study was closed early on the basis of a futility analysis; 45 of 53 enrolled patients were evaluable from an original target of 100. No difference was noted in the incidence of BM at 1 year in the TMZ and observation groups (18\% and 13\%, respectively), in median time to progression (11.7 and 10.7 months, respectively), or in median OS (27.1 and 22.5 months, respectively).",

year = "2014",

month = jan,

day = "11",

doi = "10.1016/j.cllc.2014.06.008",

language = "American English",

volume = "15",

journal = "Clinical Lung Cancer",

}

TY - JOUR

T1 - Strategies to Prevent Brain Metastasis in High-Risk Non–Small-Cell Lung Cancer: Lessons Learned From a Randomized Study of Maintenance Temozolomide Versus Observation

AU - Boggs, D. Hunter

AU - Robins, H. Ian

AU - Langer, Corey J.

AU - Traynor, Anne M.

AU - Berkowitz, Maurice J.

AU - Mehta, Minesh P.

N1 - The study was closed early on the basis of a futility analysis; 45 of 53 enrolled patients were evaluable from an original target of 100. No difference was noted in the incidence of BM at 1 year in the TMZ and observation groups (18% and 13%, respectively), in median time to progression (11.7 and 10.7 months, respectively), or in median OS (27.1 and 22.5 months, respectively).

PY - 2014/1/11

Y1 - 2014/1/11

UR - http://www.sciencedirect.com/science/article/pii/S1525730414001211

U2 - 10.1016/j.cllc.2014.06.008

DO - 10.1016/j.cllc.2014.06.008

M3 - Article

VL - 15

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

ER -

Strategies to Prevent Brain Metastasis in High-Risk Non–Small-Cell Lung Cancer: Lessons Learned From a Randomized Study of Maintenance Temozolomide Versus Observation

Disciplines

Access to Document

Other files and links

Cite this